|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
CONCURRENT USE WITH ASTEMIZOLE, REPORTED TO SIGNIFICANTLY ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
THEORETICAL POTENTIAL FOR INTERACTION WITH METFORMIN BY COMPETING FOR COMMON RENAL TUBULAR TRANSPORT SYSTEM
|
THEORETICAL POTENTIAL FOR INTERACTION WITH METFORMIN BY COMPETING FOR COMMON RENAL TUBULAR TRANSPORT SYSTEM
|
CIMETIDINE DECREASES RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED PLASMA LEVELS
|
CO-ADMINISTRATION CAN INCREASE PLASMA LEVELS OF CICLESONIDE LEADING TO INCREASED CHANCES OF CUSHING SYNDROME
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
CONCURRENT USE WITH TERFENADINE, REPORTED TO SIGNIFICANTLY ALTER THE METABOLISM OF IT; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS, LIKE PROLONGED QT INTERVAL,CARDIAC ARREST,TORSADE DE POINTES,VENTRICULAR ARRHYTHMIAS, AND DEATH HAVE BEEN REPORTED
|
PHENYTOIN ANTIEPILEPTIC ACTIVITY IS ANTAGONISED BY THE DRUG BY REDUCING THE CONVULSIVE THRESHOLD, SO PHENYTOIN DOSE HAS TO BE INCREASED
|
CYTOCHROME P450 INHIBITORS MAY INHIBIT 25 HYDROXYLATION OF DOXERCALCIFEROL, HENCE FORMATION OF ACTIVE MOITY MAY BE HINDERED
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
INCREASE RISK OF INDUCING VENTRICULAR ARRHYTHMIAS
|
RAISES THE SERUM DIGOXIN CONCENTRATION DUE TO REDUCTION IN CLEARANCE AND/OR VOLUME OF DISTRIBUTION OF THE DRUG, WITH THE IMPLICATION THAT DIGITALIS INTOXICATION MAY RESULT
|
RAISES THE SERUM DIGOXIN CONCENTRATION DUE TO REDUCTION IN CLEARANCE AND/OR VOLUME OF DISTRIBUTION OF THE DRUG, WITH THE IMPLICATION THAT DIGITALIS INTOXICATION MAY RESULT
|
CO-ADMINISTRATION MAY PRODUCE ELECTROCARDIOGRAPHIC ABNORMALITIES AND INCREASE RISK OF CONVULSIONS, IF USED IN SEVERE MALARIA, MEFLOQUINE ADMINISTRATION SHOULD BE DELAYED AT LEAST 12 HRS. AFTER THE LAST DOSE
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUININE CAUSES HYPOPROTHROMBINAEMIA SO CONCURRENT USE OF ANTICOAGULANTS NEED LESSER DOSE
|
QUININE CAUSES HYPOPROTHROMBINAEMIA SO CONCURRENT USE OF ANTICOAGULANTS NEED LESSER DOSE
|
QUININE CAUSES HYPOPROTHROMBINAEMIA SO CONCURRENT USE OF ANTICOAGULANTS NEED LESSER DOSE
|
QUININE CAUSES HYPOPROTHROMBINAEMIA SO CONCURRENT USE OF ANTICOAGULANTS NEED LESSER DOSE
|
QUININE CAUSES HYPOPROTHROMBINAEMIA SO CONCURRENT USE OF ANTICOAGULANTS NEED LESSER DOSE
|
QUININE CAUSES HYPOPROTHROMBINAEMIA SO CONCURRENT USE OF ANTICOAGULANTS NEED LESSER DOSE
|
QUININE CAUSES HYPOPROTHROMBINAEMIA SO CONCURRENT USE OF ANTICOAGULANTS NEED LESSER DOSE
|
|
|
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|